Novo Nordisk (NOVO) Fireside chat summary

Introduction and agenda

• The session, held in Vienna on 17 September 2025, focused on R&D and pipeline developments in healthcare, with an emphasis on diabetes, obesity, and related comorbidities, and included a Q&A segment with the audience.

Background and experience of the speaker

• Martin Holst Lange, Executive Vice President of R&D and Chief Scientific Officer, discussed his new role and responsibilities, highlighting the recent re-merger of research and development functions to drive scientific and strategic synergies and improve decision-making speed.

Current industry trends

• Emphasis on the growing importance of obesity and diabetes treatments, with a focus on comorbidities such as cardiovascular and kidney diseases, and cardiometabolic health.

• Real-world evidence continues to confirm the cardiovascular benefits of semaglutide, distinguishing it in the obesity and diabetes space.

• Multiple clinical trials and real-world evidence studies presented, highlighting ongoing innovation.

• The need for patient-centric approaches in clinical trial design, including flexible titration and consideration of individual patient needs, is increasingly recognized.